AR040420A1 - INHALABLE AZTREONAM FOR THE TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS - Google Patents
INHALABLE AZTREONAM FOR THE TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONSInfo
- Publication number
- AR040420A1 AR040420A1 ARP030102429A AR040420A1 AR 040420 A1 AR040420 A1 AR 040420A1 AR P030102429 A ARP030102429 A AR P030102429A AR 040420 A1 AR040420 A1 AR 040420A1
- Authority
- AR
- Argentina
- Prior art keywords
- treatment
- bacterial infections
- prevention
- pulmonary bacterial
- pseudomonas aeruginosa
- Prior art date
Links
Abstract
Un método y una composición para el tratamiento de las infecciones bacterianas pulmonares provocadas por bacterias gram-negativas adecuados para el tratamiento de infecciones provocadas por, Escherichia coli, Klebsiella pneumoniae, Klebsiella Oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, especies de Enterobacter, Serratia marcescens, y también aquéllas provocadas por Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans y Pseudomonas aeruginosa resistente a múltiples drogas utilizando una formulación concentrada de aztreonam o una sal farmacéuticamente aceptable del mismo, liberadas como una formulación en aerosol o en polvo seco.A method and composition for the treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for the treatment of infections caused by, Escherichia coli, Klebsiella pneumoniae, Klebsiella Oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens, and also those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans and Pseudomonas aeruginosa resistant to multiple drugs using a concentrated formulation of aztreonam or a pharmaceutically acceptable salt thereof, released as an aerosol or dry powder formulation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ARP030102429 AR040420A1 (en) | 2003-07-04 | 2003-07-04 | INHALABLE AZTREONAM FOR THE TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ARP030102429 AR040420A1 (en) | 2003-07-04 | 2003-07-04 | INHALABLE AZTREONAM FOR THE TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS |
Publications (1)
Publication Number | Publication Date |
---|---|
AR040420A1 true AR040420A1 (en) | 2005-04-06 |
Family
ID=42777433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030102429 AR040420A1 (en) | 2003-07-04 | 2003-07-04 | INHALABLE AZTREONAM FOR THE TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS |
Country Status (1)
Country | Link |
---|---|
AR (1) | AR040420A1 (en) |
-
2003
- 2003-07-04 AR ARP030102429 patent/AR040420A1/en not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0116757A (en) | Method for treating pulmonary infections caused by gram-negative bacteria and pharmaceutically acceptable inhalation composition. | |
CY1114621T1 (en) | INSPECTION OF INHIBITED LYSINIC AZRTEONAMINE FOR THE TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS | |
WO2011005354A3 (en) | Gallium formulation for the treatment and prevention of infectious diseases | |
JP2017510580A5 (en) | ||
NZ631469A (en) | Aerosol fluoroquinolone formulations for improved pharmacokinetics | |
KR20170008762A (en) | I- gold iphosphine compounds as antibacterial agents | |
CL2008001469A1 (en) | Use of compounds derived from 3,5-bithenyl-1,2,4-triazole for the treatment of p.aeruginosa biofilm formation in a patient with cystic fibrosis; and a pharmaceutical combination comprising a compound of formula I and an antibiotic selected from gentamicin, amikacin, tobramycin, ciprofloxacin, among others. | |
JP2018500387A5 (en) | ||
KR20170012288A (en) | I- gold iphosphine compounds as antibacterial agents | |
Cote et al. | Combinations of early generation antibiotics and antimicrobial peptides are effective against a broad spectrum of bacterial biothreat agents | |
AU2023285900A1 (en) | Method For Reducing Lung Infection | |
AR040420A1 (en) | INHALABLE AZTREONAM FOR THE TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS | |
Lin et al. | Cyclic Diguanylate G-Quadruplex Inducer-Nitric Oxide Donor Conjugate as a Bifunctional Antibiofilm Agent and Antibacterial Synergist against Pseudomonas aeruginosa with a Hyperbiofilm Phenotype | |
AR054219A1 (en) | FORMULATION OF INHALABLE AZTREONAM LISINATE FOR THE TREATMENT AND PREVENTION OF BACTERIAL PULMONARY INFECTIONS | |
CY1114144T1 (en) | INHALATED AZRONEONAM FOR THE TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS | |
Kumar et al. | Ertapenem for multiple β-lactamases producing Gram-negative bacteria causing urinary tract infections in HIV patients | |
Sumithra et al. | Efflux pump inhibitors for antibacterial therapy. | |
Chirra et al. | Antimicrobial Efficacy and Targeted Nanoparticle Delivery of Silver Ibuprofen to Treat Multi-Drug Resistant Gram-Positive and Gram-Negative Pathogens | |
Scheeren et al. | Clinical cure and mortality outcomes with ceftobiprole medocaril versus ceftazidime plus linezolid in patients with early versus late-onset hospital-acquired pneumonia. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |